Kuros Biosciences Equity 2024

Kuros Biosciences Aktienanalyse

What does Kuros Biosciences do?

Kuros Biosciences AG is a leading Swiss biotech company specializing in the development of novel products for the regeneration of bones and soft tissues. Founded in 2004 in Zurich, the company has since experienced a remarkable history of scientific progress, partnerships, and growth. Kuros' business model is based on researching and developing innovative therapy products in the fields of orthopedics and traumatology. The company relies on proprietary technologies and products based on natural body processes and cellular signals. Kuros aims to reduce the use of autologous bone or tissue transplantation and improve patient care with this approach. The company is divided into three strategic business areas: orthobiologics, neurotherapeutics, and tissue repair. The orthobiologics area includes products for the regeneration and restoration of bone defects and injuries. Kuros has developed a novel synthetic bone matrix called MagnetOs, which supports bone growth due to its bioactive properties. The neurotherapeutics area focuses on therapy products for the treatment of neurological diseases such as strokes. Kuros utilizes its expertise in cellular signaling to develop targeted and effective therapies. The third business area, tissue repair, concentrates on the development of products for the repair of soft tissues and tendons. The company has created a variety of innovative solutions based on the body's own regeneration processes in this area. Research and development are at the center of Kuros' business model as a biotech company. The company aims to continually develop new products and therapy solutions to improve patient care in the fields of orthopedics, neurology, and tissue repair. Within this framework, Kuros closely collaborates with leading scientific institutions and partners from the pharmaceutical and medtech industries. Overall, Kuros Biosciences has developed an impressive range of products based on the latest scientific knowledge, offering comprehensive solutions for the regeneration of bones, soft tissues, and nerve cells. Kuros' core business lies in the targeted marketing and distribution of these products to medical professionals and clinics. Since its founding in 2004, Kuros Biosciences AG has experienced an exciting history of progress and growth. With an innovative business model, a strong focus on research and development, and a wide range of products, the company has established itself as a key player in the biotech industry. Kuros' success is based on close collaboration with leading scientists and partners, as well as a strong commitment to meeting the needs of patient care and medical professionals. Kuros Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Kuros Biosciences's Equity

Kuros Biosciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Kuros Biosciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Kuros Biosciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Kuros Biosciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Kuros Biosciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Kuros Biosciences stock

What is the equity of Kuros Biosciences this year?

Kuros Biosciences has equity of 56.71 M CHF this year.

What was the equity of Kuros Biosciences compared to the previous year?

The equity of Kuros Biosciences has increased/decreased by -17.64% decreased compared to the previous year.

What impact does a high equity have on investors of Kuros Biosciences?

A high equity is advantageous for investors of Kuros Biosciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Kuros Biosciences?

A low equity can be a risk for investors of Kuros Biosciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Kuros Biosciences affect the company?

An increase in equity of Kuros Biosciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Kuros Biosciences affect the company?

A reduction in equity of Kuros Biosciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Kuros Biosciences?

Some factors that can affect the equity of Kuros Biosciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Kuros Biosciences so important for investors?

The equity of Kuros Biosciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Kuros Biosciences take to change the equity?

To change equity, Kuros Biosciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Kuros Biosciences pay?

Over the past 12 months, Kuros Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kuros Biosciences is expected to pay a dividend of 0 CHF.

What is the dividend yield of Kuros Biosciences?

The current dividend yield of Kuros Biosciences is .

When does Kuros Biosciences pay dividends?

Kuros Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kuros Biosciences?

Kuros Biosciences paid dividends every year for the past 0 years.

What is the dividend of Kuros Biosciences?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kuros Biosciences located?

Kuros Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kuros Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kuros Biosciences from 11/17/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Kuros Biosciences pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Kuros Biosciences in the year 2023?

In the year 2023, Kuros Biosciences distributed 0 CHF as dividends.

In which currency does Kuros Biosciences pay out the dividend?

The dividends of Kuros Biosciences are distributed in CHF.